Imbalance of regulatory T cells in human autoimmune diseases
Version of Record online: 22 DEC 2005
Volume 117, Issue 3, pages 289–300, March 2006
How to Cite
Dejaco, C., Duftner, C., Grubeck-Loebenstein, B. and Schirmer, M. (2006), Imbalance of regulatory T cells in human autoimmune diseases. Immunology, 117: 289–300. doi: 10.1111/j.1365-2567.2005.02317.x
- Issue online: 13 FEB 2006
- Version of Record online: 22 DEC 2005
- Received 19 August 2005; revised 2 November 2005; accepted 15 November 2005.
- autoimmune disease;
- regulatory T lymphocyte;
- somatic cell therapy;
- suppressor cells
The breakdown of mechanisms assuring the recognition of self and non-self is a hallmark feature of autoimmune diseases. In the past 10 years, there has been a steadily increasing interest in a subpopulation of regulatory T cells, which exert their suppressive function in vitro in a contact-dependent manner and preferentially express high levels of CD25 and forkhead and winged-helix family transcription factor forkhead box P3 (FOXP3) (TREGs). Recent findings of changed prevalences and functional efficiencies indicate that these TREGs play a unique role in autoimmune diseases. Clinical findings in patients with mutated FOXP3 genes and a specific polymorphism in the promotor region of FOXP3 also support the role of FOXP3 as a ‘master control gene’ in the development and functioning of TREGs. Both altered generation of TREGs and insufficient suppression of inflammation in autoimmune diseases are considered to be crucial for the initiation and perpetuation of disease. TREG-related somatic cell therapy is considered as an intriguing new intervention to approach autoimmune diseases.